

Implementing non-animal approaches to human and veterinary vaccine testing: Achieving scientific and regulatory success for rabies and beyond

October 16-17, 2018 - Bethesda, Maryland

Biosketch

[Return to the list](#)



Dean Smith, Ph.D.

IABS-NA Affiliation: Presenter, Implementation non-animal approaches to human and veterinary vaccine testing: Achieving scientific and regulatory success for rabies and beyond, Bethesda Maryland, 16-17 October 2018

Organization: Centre for Biologics Evaluation, Health Canada

Ottawa, Ontario, Canada

Presentation: "Substituting in vitro for in vivo vaccine potency and safety assays: science versus the fear factor". Tuesday, October 16, 2018, 10:30 to 10:50 AM.

Dean Smith, Ph.D., Immunologist and Senior Scientific Evaluator in the Center for Biologics Evaluation of Health Canada with over 20 years of experience in regulatory science in support of innovation in vaccine development, manufacturing and quality control. Dedicated to uphold standards while striving to provide value to sponsors through regulatory engagements in his work with Health Canada, Dr. Smith is also engaged with the WHO on vaccine and vaccine stability guidance development and implementation. For the past eight years, he's been Health Canada's representative to the European Directorate of Quality of Medicines, Group 15 (Vaccines), which supports the European Pharmacopeia. He also serves on the Science and Ethics Advisory Committee for VAC2VAC under the European Vaccines Initiative.

Dr. Smith's graduate work was completed in the Department of Medical Microbiology and Immunology

at University of Alberta, where his research focused on autoimmunity and viral vector-based gene therapy. Prior to joining Health Canada, he was a Research Associate within the Vaccine Design Division of the National Research Council (Ottawa) focusing on BCG based anti-cancer vaccines and T cell memory.

When Dr. Smith initially joined Health Canada, it was to re-establish a Smallpox Vaccine Quality Control Laboratory post-9/11. The work expanded to include rabies, flavivirus and rotavirus; transitioning to BCG, typhoid, cholera and other bacterial vaccines. He has worked in and managed both the Viral and Bacterial Vaccines Divisions, and the Hemostatic Agents and Blood Substitutes Division. As a result, he has a range of biologics based scientific and regulatory experience.



IABS - Rue de la Vallée, 3 - 1204 Geneva - Switzerland

Tel : +41 22 301 10 36 - Fax : +41 22 301 10 37 - www.iabs.org